Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.16B |
| 2 |
Hershey
HSY
|
+$663M |
| 3 |
Lockheed Martin
LMT
|
+$622M |
| 4 |
Altria Group
MO
|
+$525M |
| 5 |
Pfizer
PFE
|
+$499M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.76B |
| 2 |
Merck
MRK
|
+$2.35B |
| 3 |
Automatic Data Processing
ADP
|
+$1.57B |
| 4 |
Blackstone
BX
|
+$1.38B |
| 5 |
Illinois Tool Works
ITW
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.85% |
| 2 | Financials | 12.71% |
| 3 | Healthcare | 11.72% |
| 4 | Consumer Discretionary | 10.09% |
| 5 | Industrials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Adaptive Biotechnologies
ADPT
$3.78B
| $2.79M | ﹤0.01% |
869,782
+113,850
| +15% | +$441K |
|
|
ENFN
2502
DELISTED
Enfusion, Inc.
ENFN
| $2.79M | ﹤0.01% |
301,560
+8,957
| +3% | +$78.8K |
|
2503
Theravance Biopharma
TBPH
$874M
| $2.79M | ﹤0.01% |
310,501
-3,510
| -1% | -$32.5K |
|
2504
DocGo
DCGO
$63.2M
| $2.76M | ﹤0.01% |
682,644
+14,792
| +2% | +$55.8K |
|
2505
Rayonier Advanced Materials
RYAM
$603M
| $2.75M | ﹤0.01% |
576,002
+402,508
| +232% | +$1.71M |
|
2506
Custom Truck One Source
CTOS
$2.58B
| $2.75M | ﹤0.01% |
472,958
+16,704
| +4% | +$104K |
|
2507
Vanda Pharmaceuticals
VNDA
$319M
| $2.75M | ﹤0.01% |
668,180
+23,051
| +4% | +$92.3K |
|
2508
Vitesse Energy
VTS
$642M
| $2.71M | ﹤0.01% |
114,337
+45,618
| +66% | +$1M |
|
|
NXDR
2509
Nextdoor Holdings
NXDR
$892M
| $2.71M | ﹤0.01% |
1,203,473
+52,933
| +5% | +$98.9K |
|
2510
Aurinia Pharmaceuticals
AUPH
$1.91B
| $2.7M | ﹤0.01% |
538,958
+100,767
| +23% | +$684K |
|
2511
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.9B
| $2.69M | ﹤0.01% |
29,264
-523
| -2% | -$47.9K |
|
2512
Wave Life Sciences
WVE
$1.16B
| $2.68M | ﹤0.01% |
433,577
+263,884
| +156% | +$1.32M |
|
2513
Biomea Fusion
BMEA
$90.4M
| $2.68M | ﹤0.01% |
178,935
+2,138
| +1% | +$35.2K |
|
2514
PubMatic
PUBM
$621M
| $2.67M | ﹤0.01% |
112,760
-6,592
| -6% | -$118K |
|
2515
Applied Digital
APLD
$8.97B
| $2.66M | ﹤0.01% |
620,868
+86,168
| +16% | +$435K |
|
2516
Lindblad Expeditions
LIND
$2.17B
| $2.65M | ﹤0.01% |
284,251
+2,516
| +0.9% | +$23.2K |
|
2517
CRH
CRH
$65.7B
| $2.65M | ﹤0.01% |
30,725
+7,464
| +32% | +$571K |
|
|
PLGO
2518
Pelagos Insurance Capital
PLGO
$2.15B
| $2.65M | ﹤0.01% |
135,893
+100,713
| +286% | +$1.48M |
|
2519
National Grid
NGG
$80.5B
| $2.64M | ﹤0.01% |
41,006
+14,101
| +52% | +$892K |
|
2520
Aehr Test Systems
AEHR
$3.55B
| $2.63M | ﹤0.01% |
212,107
+2,437
| +1% | +$40.6K |
|
2521
Organogenesis Holdings
ORGO
$309M
| $2.59M | ﹤0.01% |
910,739
+76,731
| +9% | +$261K |
|
2522
Stem
STEM
$53.4M
| $2.58M | ﹤0.01% |
58,795
+8,818
| +18% | +$490K |
|
2523
Ranpak Holdings
PACK
$491M
| $2.56M | ﹤0.01% |
325,846
+14,593
| +5% | +$76.7K |
|
2524
Frontier Group Holdings
ULCC
$1.86B
| $2.56M | ﹤0.01% |
315,592
+20,677
| +7% | +$134K |
|
2525
Microvision
MVIS
$85.2M
| $2.56M | ﹤0.01% |
92,603
-5,366
| -5% | -$182K |
|
Similar funds
Charles Schwab's Q1 2024 Portfolio in Review
As of Q1 2024, Charles Schwab held 3,573 positions worth $433B, up 10% from $394B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 3.8%. Charles Schwab opened 35 new positions and exited 102, leaving the 3,573-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2024 buy was Schwab Fundamental US Large Company Index ETF: 3,608,604 shares worth $81.1M.
- Charles Schwab added most to Bristol-Myers Squibb in Q1 2024, an estimated $2.16B increase.
- Charles Schwab's biggest Q1 2024 reduction was Broadcom, cutting an estimated $2.76B.
- Charles Schwab fully exited Splunk Inc in Q1 2024, selling an estimated $104M.
- Charles Schwab's ten largest holdings make up 20% of its $433B portfolio in Q1 2024.
- Charles Schwab opened 35 new positions and closed 102 in Q1 2024.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $433B.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.